Evidence map›Paper›PMID 32405660›Full record

SynthesisInternational urogynecology journal2021

Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome?

Jia-Pei Wu, Liao Peng, Xiao Zeng, Hao Li, Hong Shen, De-Yi Luo

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in International urogynecology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Pharmacological Management of Urinary Incontinence: Current and Emerging Treatment.Clinical pharmacology : advances and applications · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jia-Pei Wu *Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Liao Peng *Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Xiao Zeng *Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Hao LiDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Hong ShenDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
De-Yi LuoDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China. luodeyi1985@163.com.ORCID https://orcid.org/0000-0002-9436-036X
Sichuan University · CN

Funding

1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University ZY2017310the National Natural Science Fund of China 81770673
6 · The paper itself

Abstract

purposePrevious studies have included a limited number of randomized controlled trials (RCTs) and compared limited parameters after treatment with imidafenacin and other anticholinergic drugs (ADs) for overactive bladder syndrome (OAB), and controversy about the superiority of these ADs still remains. We aim to update the evidence and provide better clinical guidance.

methodsA systematic search of PubMed, Embase, ClinicalTrial.gov and Cochrane Library Central Register of Controlled Trials was conducted from January 2007 to April 2019. Meta-analysis of all published RCTs comparing imidafenacin with other ADs in patients with OAB was performed. The primary outcomes were the changes in OAB symptoms and OAB symptom score (OABSS). Secondary outcomes included adverse events (AEs) and the dropout rate related to AEs.

resultsA total of 6 studies including 7 RCTs involving 1430 patients with mean follow-up of 23.43 weeks were included. All ADs improved OAB symptoms. Regarding efficacy, these drugs had similar efficacy in voids, urgency episodes, urgency incontinence episodes, incontinence episodes and OABSS. However, imidafenacin performed better in the reduction of nocturia episodes (MD = -0.24, 95% CI -0.44 to -0.04, P = 0.02). Moreover, imidafenacin was associated with a statistically lower dry mouth rate (RR = 0.87, 95% CI 0.75-1.00, P = 0.04), lower constipation rate (RR = 0.68, 95% CI 0.50-0.93, P = 0.01) and lower AE-related withdrawal rate (RR = 0.51, 95% CI 0.29-0.89, P = 0.02). There was no significant difference in terms of other complications.

conclusionsIn conclusion, imidafenacin was comparable to other ADs in the treatment of OAB. Moreover, imidafenacin presented a lower dry mouth rate, lower constipation rate and higher adherence and persistence.

Indexed as

Pharmaceutical PreparationsUrinary Bladder, OveractiveHumansImidazolesMuscarinic AntagonistsTreatment OutcomeimidafenacinImidazolesMuscarinic AntagonistsPharmaceutical PreparationsAnticholinergic drugAntimuscarinicsImidafenacinNovel antimuscarinic agentOveractive bladder syndromeQuality of life

Identifiers

PMID32405660
OpenAlexW3024457109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.